Cytokinetics, Incorporated (CYTK)
USD 46.36
(-2.97%)
USD 46.36
(-2.97%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 7.53 Million | 94.58 Million | 70.42 Million | 55.82 Million | 26.86 Million | 31.5 Million |
| Cost of Revenue | 330.12 Million | 240.81 Million | 159.93 Million | 96.95 Million | 86.12 Million | 89.13 Million |
| Gross Profit | -322.59 Million | -146.22 Million | -89.51 Million | -41.12 Million | -59.25 Million | -57.63 Million |
| Operating Expenses | 173.61 Million | 177.97 Million | 96.8 Million | 52.82 Million | 39.61 Million | 31.28 Million |
| Selling, General and Administrative Expenses | 173.61 Million | 177.97 Million | 96.8 Million | 52.82 Million | 39.61 Million | 31.28 Million |
| Research and Development Expenses | - | 6.58 Million | 159.93 Million | 96.95 Million | 86.12 Million | 89.13 Million |
| Other Expenses | - | -6.58 Million | -159.93 Million | -96.95 Million | -86.12 Million | - |
| Cost and Expenses | 503.73 Million | 418.79 Million | 256.74 Million | 149.77 Million | 125.73 Million | 120.41 Million |
| Operating Income | -496.2 Million | -324.2 Million | -186.31 Million | -93.94 Million | -98.86 Million | -88.91 Million |
| Interest Expense | 57.66 Million | 51.15 Million | 29.33 Million | 38.67 Million | 27.36 Million | 21.56 Million |
| Income Tax Expense | - | 13.59 Million | 27.05 Million | 36.84 Million | 27.36 Million | 4.19 Million |
| Earnings before Tax | -526.24 Million | -388.95 Million | -215.31 Million | -127.29 Million | -121.69 Million | -106.28 Million |
| Net Income | -526.24 Million | -402.55 Million | -242.37 Million | -164.13 Million | -149.05 Million | -106.28 Million |
| Earnings Per Share Basic | -5.45 | -4.48 | -3.15 | -2.54 | -2.59 | -1.95 |
| Earnings Per Share Diluted | -5.45 | -4.48 | -3.15 | -2.54 | -2.59 | -1.95 |
| Weighted Average Shares Outstanding | 96.52 Million | 89.82 Million | 76.88 Million | 64.52 Million | 57.57 Million | 54.42 Million |
| Weighted Average Shares Outstanding (Diluted) | 96.52 Million | 89.82 Million | 76.88 Million | 64.52 Million | 57.57 Million | 54.42 Million |
| Gross Margin | -42.84 | -1.55 | -1.27 | -0.74 | -2.21 | -1.83 |
| EBIT Margin | -60.65 | -3.31 | -2.64 | -1.59 | -3.46 | -2.69 |
| Profit Margin | -69.89 | -4.26 | -3.44 | -2.94 | -5.55 | -3.37 |
| EBITDA | -456.68 Million | -329.4 Million | -176.34 Million | -86.78 Million | -93.03 Million | -83.48 Million |
| Earnings Before Tax Margin | -65.90 | -3.43 | -2.65 | -1.68 | -3.68 | -2.82 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 249 Thousand | 835 Thousand | 1.67 Million | 7.53 Million | 378 Thousand | 867 Thousand |
| Cost of Revenue | 2.4 Million | 2.33 Million | 6.33 Million | 11.89 Million | 82.53 Million | 83.19 Million |
| Gross Profit | -2.15 Million | -1.49 Million | -4.66 Million | -4.36 Million | -82.15 Million | -82.32 Million |
| Operating Expenses | 128.01 Million | 124.73 Million | 122.75 Million | 491.84 Million | 40.11 Million | 39.72 Million |
| Selling, General and Administrative Expenses | 50.82 Million | 45.5 Million | 44.11 Million | - | 40.11 Million | 39.72 Million |
| Research and Development Expenses | 77.19 Million | 79.23 Million | 78.64 Million | - | 378 Thousand | 867 Thousand |
| Other Expenses | 200 Thousand | 80.73 Million | 163.72 Million | 326.09 Million | 82.15 Million | 82.32 Million |
| Cost and Expenses | 130.42 Million | 127.07 Million | 129.09 Million | 503.73 Million | 122.64 Million | 122.91 Million |
| Operating Income | -130.17 Million | -126.23 Million | -127.41 Million | -496.2 Million | -122.26 Million | -122.04 Million |
| Interest Expense | 24.29 Million | 17.32 Million | 17.06 Million | 57.66 Million | 13.99 Million | 13.36 Million |
| Income Tax Expense | - | 2.28 Million | 1.84 Million | 11.72 Million | 6.87 Million | 6.65 Million |
| Earnings before Tax | -143.31 Million | -135.64 Million | -136.89 Million | -526.24 Million | -129.42 Million | -128.63 Million |
| Net Income | -143.31 Million | -135.64 Million | -136.89 Million | -526.24 Million | -129.42 Million | -128.63 Million |
| Earnings Per Share Basic | -1.31 | -1.33 | -1.38 | - | -1.35 | -1.34 |
| Earnings Per Share Diluted | -1.31 | -1.33 | -1.38 | - | -1.35 | -1.34 |
| Weighted Average Shares Outstanding | 109.24 Million | 101.92 Million | 99.06 Million | 96.52 Million | 96.07 Million | 95.75 Million |
| Weighted Average Shares Outstanding (Diluted) | 109.24 Million | 101.92 Million | 99.06 Million | 96.52 Million | 96.07 Million | 95.75 Million |
| Gross Margin | -8.66 | -1.79 | -2.79 | -0.58 | -217.34 | -94.96 |
| EBIT Margin | -513.12 | -148.39 | -72.42 | - | -305.36 | -132.95 |
| Profit Margin | -575.57 | -162.45 | -81.88 | -69.89 | -342.39 | -148.37 |
| EBITDA | -127.76 Million | -123.9 Million | -121.08 Million | - | -115.42 Million | -115.27 Million |
| Earnings Before Tax Margin | -522.78 | -151.18 | -76.21 | -65.90 | -323.45 | -140.77 |
ACSAF
1215
3005
OCDDY
CFGX
PSX